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Background and the purpose of the study: Affinity-based target deconvolution is an emerging method for the
identification of interactions between drugs/drug candidates and cellular proteins, and helps to predict potential
activities and side effects of a given compound. In the present study, we hypothesized that a part of safranal
pharmacological effects, one of the major constituent of Crocus sativus L., relies on its physical interaction with
target proteins.
Methods: Affinity chromatography solid support was prepared by covalent attachment of safranal to agarose beads.
After passing tissue lysate through the column, safranal-bound proteins were isolated and separated on SDS-PAGE or
two-dimensional gel electrophoresis. Proteins were identified using MALDI-TOF/TOF mass spectrometry and Mascot
software.
Results and major conclusion: Data showed that safranal physically binds to beta actin, cytochrome b-c1 complex
sub-unit 1, trifunctional enzyme sub-unit beta and ATP synthase sub-unit alpha and beta. These interactions may
explain part of safranal’s pharmacological effects. However, phenotypic and/or biological relevance of these
interactions remains to be elucidated by future pharmacological studies.
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Crocus sativus L., commonly known as saffron, is a peren-
nial stemless herb belonging to the Iridaceae family. The
most important constituents of saffron are safranal,
crocin, picrocrocin and crocetin [1]. Safranal (2,6,6-
trimethyl-1,3-cyclohexadiene-1-carboxaldehyde; Figure 1)
is a volatile monoterpene aldehyde that is produced by
acidic hydrolysis of picrocrocin [2], and is responsible for
the saffron’s unique aroma [3]. While safranal is the major
component of saffron’s oil, its presence in the plant’s
extract is less than 1% [4].
Saffron is a medicinal plant endowed with a plethora
of biological and pharmacological activities and a long
history of applications in the Islamic traditional medi-
cine [5,6]. Safranal is believed to play a key role in the
observed biological activities of saffron. Modern
pharmacological studies have unveiled antioxidant
[3,7,8], genoprotective [9], bronchodilatory [10], cyto-
toxic [2,11], antitussive [12], anticonvulsant [13,14],* Correspondence: abnouskh@mums.ac.ir
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distribution, and reproduction in any mediumantinociceptive [15], neuroprotective [16], antiabsence
[17], antidepressant [18], hypotensive [19], anxiolytic
and hypnotic [20] effects of safranal.
Traditionally, drug discovery has been based on the
observation of a phenotypic change after application of a
natural or synthetic compound. Isolation and identifica-
tion of molecular targets of a natural product or drug
helps to elucidate its mechanism of action and side effects
and also predict potential activities. This approach is
called target deconvolution [21]. Finding new potential
therapeutic effects or un-anticipated side effects can be
considered as benefits of target deconvolution.
In the present study, we looked for the spectrum of
cellular proteins that could interact with safranal. To
this end, an affinity chromatography-based purification
followed by two-dimensional gel electrophoresis isola-
tion method was used. Potential targets of safranal were
finally unraveled through proteomic identification.
Material and methods
Animals and tissue samples
Animal study was approved by the Institutional Ethics
Committee. Animals were housed at temperature of 25 ±entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Chemical structure of safranal.
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water. Twelve male BALB/c mice (6 weeks old, 20–30 g
weight) were sacrificed by decapitation. Liver, heart,
kidney and brain of mice were washed using 0.9% normal
saline solution. Tissues were immediately frozen in liquid
nitrogen and stored at −80°C until use.
Preparation of tissue extracts
Liver, heart, kidney and brain tissues (200–400 mg) were
homogenized in extraction buffer [with the ratio of 1:5
(w:v)] containing 50 mM Tris (pH 7.4), 2 mM EGTA,
2 mM EDTA, 2 mM Na3VO4, 1% Triton X-100 and 10
mM 2-mercaptoethanol, with further addition of a few
crystals of the protease inhibitor phenylmethylsulfonyl
fluoride (PMSF) immediately before homogenization of
tissue. Homogenization was performed using a Polytron
Homogenizer (Kinematica, Switzerland) followed by
sonication (UP100H, Hielscher) for 40 seconds. After
centrifugation (Hettich Universal 320R, Germany) at
25,000 g for 10 min at 4°C, the supernatant was stored
on ice. Protein contents were measured using a Bradford
protein assay kit (BioRad). The same amount of proteins
was used for each experiment.
Preparation of safranal-resin conjugate
Safranal was covalently bound to matrix using PharmaLink
Kit (Pierce) according to the manufacturer’s instruc-
tions. Briefly, agarose beads containing immobilized
diaminodipropylamine (DADPA) side chain were equili-
brated in 4 mL coupling buffer (0.1 M MES, 0.15 M
NaCl, pH 4.7) and 50% ethanol. Safranal (100 mg) was
dissolved in 2 mL of coupling buffer and transferred to
resin slurry. Coupling reaction was started by adding
200 μL of coupling reagent (37% formaldehyde solution)
to the resin/safranal mixture. Reaction mixture was in-
cubated for 72 hrs at 50°C. Resin slurry was transferred
to a column and washed 12 times each time with 2 mLof wash buffer (0.1 M Tris, pH 8.0) and 50% ethanol to
remove unbound safranal. Flow-through fractions were
collected and pooled. Amount of unbound safranal was
calculated by measuring pooled flow through absorb-
ance at 314.8 nm using visible spectroscopy (CECIL
9000 Series) [22].
Affinity chromatography
Protein targets of safranal were isolated using affinity
chromatography. Briefly, columns with and without
(as control) bound safranal were equilibrated in binding buffer
(50 mM Tris, pH 7.4, 2 mM EGTA, 2 mM EDTA, 2 mM
Na3VO4, 1% Triton X-100, and 10 mM 2-mercaptoethanol).
Tissue extracts were incubated with control column resin for
30 min in 4°C. After a brief centrifugation at 1,000 g
for 1 min, supernatants were transferred to affinity col-
umn. After 30 min of incubation at 4°C, affinity column
was washed 4 times, each time with 2 ml of binding buffer
to remove unbound cellular components. Safranal target
proteins were then eluted with 2 mL of 2 M NaCl in
binding buffer. Elution was repeated 3 more times and
fractions were pooled. Presence of proteins in fractions
was tested using Bradford protein assay kit (BioRad).
Pooled fractions were dialyzed using a 2,000 Da cutoff
membrane in order to remove electrolytes. To concen-
trate target proteins, samples were freeze dried and
stored at −20°C until use.
Separation of target proteins using SDS-PAGE
Freeze dried samples from Kidney and liver were
dissolved in 20 μL of homogenization buffer containing
Tris 50 mM (pH: 7.4), 2 mM EDTA, 10 mM NaF, 1 mM
Na3VO4, 10 mM β- glycerol-phosphate, 0.2% W/V
sodium deoxycholate, 1 mM phenylmethylsulfonyl
fluoride (PMSF), and complete protease inhibitor cocktail
(Sigma, P8340). After addition of 20 μL of 2× SDS buffer,
samples were incubated in boiling water for 5 min and
then subjected to SDS-PAGE electrophoresis (BioRad).
Gels were silver stained and protein bands were excised
and collected in microtubes.
Two-dimensional gel electrophoresis
Proteins were dissolved to a final concentration of 125 μg/
125 μL in rehydration buffer [containing 6 M urea, 2 M
thiourea, 2% CHAPS, 50 mM Dithiothreitol (DTT), 20%
Bio-Lyte (BioRad)]. Non-linear immobilized pH gradient
(IPG) strips (pH range: 3–10) were used to separate
safranal target proteins based on their isoelectric point.
Following passive rehydration at room temperature for 12
hrs, isoelectric focusing was performed using PROTEAN
IEF CELL (BioRad) at 4000 V for 11 hrs. IPGs were incu-
bated in equilibration buffer [375 mM Tris (pH 8.8), 6 M
Urea, 2.5% SDS and 30% glycerol] for 20 min. IPGs were
placed on top of 12% SDS-PAGE and sealed with heated
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0.5% agarose, 0.1% SDS and small amount of tracking dye
bromophenol blue]. Electrophoresis was performed for 80
min at 120 V. Gels were silver stained and protein spots
were excised and collected in microtubes.
In-gel digestion
Gel slices were incubated in destaining buffer (50 MeOH,
5% acetic acid) at room temperature overnight. Destaining
was repeated with fresh buffer for 2 more hrs. Gel slices
were dehydrated in acetonitrile for 30 min and dried in
vacufuge. Gels were then covered with reducing buffer
(1.5 mg/mL in 100 mM ammonium bicarbonate) for 1 h.
Protein alkylation was performed by incubation of gel
slices in 100 μL of 10 mg/mL iodoacetamide in 100 mM
ammonium bicarbonate for 30 min at room temperature.
Afterwards, gel slices were washed using 0.5 mL of
100 mM ammonium bicarbonate. After dehydration
(using acetonitrile) and drying (in vacufuge), 50 μL of
20 μg/mL trypsin was added to each gel slice and incu-
bated on ice (5 min) and then overnight. Peptides were
extracted in 3 steps by adding 100 μL of 100 mM ammo-
nium bicarbonate, 100 μL extraction solution (50% aceto-
nitrile and 5% formic acid) and 150 μL extraction solution,
respectively. Samples were dried down to a final volume of
15 μL in vacufuge. Finally, samples were desalted using
ZipTipW μC-18 (Millipore). Eluted samples were stored
at −20°C until use.
Mass spectrometry analysis
Mass analysis was performed at the Genome Research
Centre, University of Hong Kong, using a 4800 MALDI-Figure 2 FT-IR spectrum of safranal and safranal-resin complex.TOF/TOF analyzer (ABI). Data were searched against
both NCBInr and SwissProt databases. Mascot software
was used to analyze Mass data. Mascot search parameters
were set as follow: Taxonomy: Rat, Fixed modification:
Carbamidomethyl (C), Variable modification: Oxidation
(M), MS/MS fragment tolerance: 0.2 Da, Precursor toler-
ance: 75 ppm, peptide charge: +1, monoisotopic. Proteins
with a score of > 30 and confidence interval (CI) > 95%
were accepted.
Results
Preparation of safranal-resin conjugate
Safranal was covalently attached to DADPA chain of agar-
ose beads using the Mannich reaction. Briefly, formalde-
hyde reacts with the primary amino group to produce
highly reactive iminium group. This group can react with
active hydrogen on safranal ring. Yield of safranal-resin
conjugation was calculated to be 90%. Unbound safranal
was washed away. Presence of safranal in final product
was confirmed by FT-IR (Figure 2).
In the IR spectrum of safranal resin complex, the
aldehyde (C=O) group of safranal was observed at
1638.14 cm-1, which is similar to its position in pure
safranal C=O (1637.11 cm-1).
Target proteins of safranal in liver
Affinity chromatography was performed to find cellular
targets of safranal in different organs such as liver, heart,
kidney and brain. There are two types of interactions
between stationary phase and cellular proteins: specific
interaction between safranal and target proteins and
unspecific binding between proteins and other parts of
Table 1 Molecular targets of safranal as identified by






1 ATP synthase sub-unit
alpha
485 100 56 KDa/
5.19
2 ATP synthase sub-unit beta 485 100 56 KDa/
5.19
3 Beta-actin-like protein 2 215 100 42 KDa/
5.3
4 Cytochrome b-c1 complex
sub-unit 1




258 100 51 KDa/
4.82
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cific binding of non-target proteins, tissue extracts were
incubated with control agarose beads. After a brief cen-
trifugation, supernatant was incubated with safranal-
resin stationary phase. Target proteins were eluted and
subjected to two-dimensional gel electrophoresis. After
in-gel digestion of protein spots, MALDI TOF/TOF
mass spectrometry was used for their identification.
Mass data were analyzed using Mascot software.
Cytochrome b-c1 complex sub-unit 1, trifunctional
enzyme sub-unit beta and ATP synthase sub-units alpha
and beta were identified as safranal targets in liver
(Figure 3, Table 1, Additional file 1).
Targets of safranal in kidney, heart and brain
Beta-actin-like protein 2 was identified as cellular targets
of safranal in kidney, heart and brain (Figure 4, Table 1,
Additional file 1).
Discussion
Drugs are normally discovered based on their ability to
show a certain desired biological outcome. The conven-
tional approach for drug discovery from natural resources
mainly starts with the pharmacological screening of crude
extracts followed by sequential fractionation and finally
isolation and purification of bioactive phytochemicals.
During recent years, the advent of high-throughput mass
spectrometry-based techniques has enabled the scientists
to unveil molecular targets of small molecules of either
natural or synthetic entity. Such a target deconvolution
strategy not only provides an invaluable solution for
exploring the molecular mechanisms behind the observed
phenotypic effects of a drug/drug candidate (retrospective
approach), but is also a useful tool for predicting theFigure 3 SDS-PAGE electrophoresis of safranal targets in liver
extract. Spots were identified as cytochrome c1 complex sub-unit 1,
trifunctional enzyme sub-unit beta and ATP synthase sub-unit alpha
and beta.potential biological and pharmacological activities of any
natural or lead compound prior to the start of pharmaco-
logical studies. Having known the molecular targets,
prediction of plausible adverse events is also possible due
to the well-documented roles of numerous proteins in the
pathogenesis of certain disorders [21].
Affinity-based target deconvolution methods always
carry the risk of identifying interactions with proteins that
have no pharmacological relevance (false positives), des-
pite being targets of the compound. Activity or phenotype
based assays are essential to discriminate between positive
and false-positive interactions and confirm functional
effects [21].
In the present study, the fact that physical interaction is
a prerequisite for functional effects was used to affinity
purify target proteins of safranal. Our data showed that
safranal binds to beta actin, cytochrome b-c1 complex
sub-unit 1, trifunctional enzyme sub-unit beta, and ATP
synthase sub-units alpha and beta.
Beta actin like protein 2 was identified as one of the
safranal protein targets. Actin filaments help in maintaining
cell morphology and functions such as adhesion, motility,
exocytosis, endocytosis and cell division. Natural products
like cytochalasin and jasklapinolide that interact with
actin polymerization have cytotoxic effects [23]. In
previous studies, saffron and safranal were shown to
possess cytotoxic activities and inhibit the growth of
human cancer cells. In light of the present findings,
depolymerization of actin filaments by safranal could
explain part of the observed cytotoxic effects of safranal
[24,25]. However, a possible contribution of antioxidant
properties to the cytotoxicity of safranal needs further
investigation due to the controversies over the conse-
quence of blunting ROS on the fate of cancerous cell
[26,27]. Reported cytotoxic effects of antioxidants,
including safranal, have been mainly based on in vitro
cell line studies, for which serious arguments have been
raised [28]. In addition, it has been proposed that anti-
oxidant therapy may deplete cellular reservoir of
Figure 4 SDS-PAGE and two-dimensional gel electrophoresis of safranal targets in heart (a), kidney (b) and brain(c) extract. Spots were
identified as Beta-actin-like protein 2.
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ition of neovascularization and metabolism [29].
Aside from the aforementioned effects, safranal also
interacts with cytochrome b-c1. The most conserved
role of these cytochromes is in the electron transport
chain powering oxidative phosphorylation. Moreover,
cytochrome c release into the cytosol is particularly
associated with activation of the intrinsic apoptotic
pathway [30].
The mitochondrial trifunctional protein (MTP) is a
heterotrimeric protein that consists of four α-sub-units
and four β-sub-units and catalyzes the mitochondrial
β-oxidation of long-chain fatty acids. Safranal may alter
mitochondrial fatty acid oxidation by binding to this
enzyme [31].
ATP synthase is a key enzyme of mitochondrial energy
conversion [32]. Ahmad and Laughlin [33] discussed that
dietary polyphenols and amphibian antimicrobial/antitumor
peptides inhibit ATP synthase. Inhibition of ATP synthase
may cause energy deprivation and increase ROS produc-
tion. High ROS content induces cellular necrosis and/or
apoptosis [32]. Our experiment showed that safranal may
physically interact with this enzyme.
Although physical interaction with cellular proteins is a
prerequisite for pharmacological effects of drugs in many
instances, biological relevance of such interactions remain
to be elucidated by appropriately designed experimental
investigations. The necessity of conducting such investi-
gations would be more evident when taking into ac-
count the fact that many drug-target interactions do
not translate into a significant alteration in the protein
function and thereby any considerable pharmacological
or clinical effect.Conclusion
Evidence from the present study suggested that beta actin,
cytochrome b-c1 complex sub-unit 1, trifunctional en-
zyme sub-unit beta and ATP synthase sub-unit alpha and
beta could be regarded as potential cellular targets of
safranal. Activity- or phenotype-based assays are essen-
tial to elucidate the inhibitory or stimulatory effects of
safranal on its targets.
Additional file
Additional file 1: Results from Mascot search are available as
supporting information.
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